Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 11, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/jpm11050421
Keywords
CFTR; human nasal epithelial cells; rectal biopsies; intestinal organoids; CFTR modulators; theranostic
Funding
- FCT/MCTES Portugal [UIDB/04046/2020, UIDP/04046/2020, FCT/02/SAICT/2017/28800]
- EU [H2020-SC1-2017-755021]
- CF Trust-United Kingdom [SRC 013]
- CFF-United States [AMARAL19G0]
- Vertex Pharmaceuticals
Ask authors/readers for more resources
This study demonstrates that pHNE cells can serve as a model for evaluating the efficacy of CFTR modulator drugs for patients with CF and rare mutations, based on the correlation between CFTR basal function in pHNEs with rectal biopsies and CFTR rescue in pHNEs with intestinal organoids.
As highly effective CFTR modulator therapies (HEMT) emerge, there is an unmet need to find effective drugs for people with CF (PwCF) with ultra-rare mutations who are too few for classical clinical trials and for whom there are no drug discovery programs. Therefore, biomarkers reliably predicting the benefit from CFTR modulator therapies are essential to find effective drugs for PwCF through personalized approaches termed theranostics. Here, we assess CFTR basal function and the individual responses to CFTR modulators in primary human nasal epithelial (pHNE) cells from PwCF carrying rare mutations and compare these measurements with those in native rectal biopsies and intestinal organoids, respectively, in the same individual. The basal function in pHNEs shows good correlation with CFTR basal function in rectal biopsies. In parallel, CFTR rescue in pHNEs by CFTR modulators correlates to that in intestinal organoids. Altogether, results show that pHNEs are a bona fide theranostic model to assess CFTR rescue by CFTR modulator drugs, in particular for PwCF and rare mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available